Dr Perkins, talking at the IV International Workshop on Myeloma Genetics, Pharmacogenomics & Novel Therapeutics discusses the work of the Multiple Myeloma Research Foundation (MMRF), whose main focus is to accelerate the development of therapeutics for myeloma patients. The MMRF provides grants for researchers and studies looking at treatments for myeloma.The workshop was supported by an unrestricted medical education grant from the following companies; Celgene, Bristol Myers Squibb, Johnson and Johnson, Takeda Millennium, Novartis Oncology, Cephalon and Onyx Pharmaceuticals.